SVRA logo

SAVARA INC

SVRANASDAQ
🏆 #2452 by market capUS Equity
$766.32▲ $36.40 (+4.75%)
Simulated price
🔔
Track SVRA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.8%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1.04B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
4010.4x
Expensive
Otter Score
60
Fair
No chart data available for SVRA.

Trading Snapshot

Day Range
$754.08 – $774.52
52-Week Range
$3.34 – $7.01
Volume
$3.36B
Avg Volume
$4.44B
Shares Outstanding
204.9M
Next Earnings
Oct 25, 2026

Fundamentals Snapshot

Annual Revenue
$259,744
Last Q Revenue
$69,009
P/E Ratio
—
P/S Ratio
4010.4x
EPS (TTM)
$-0.58
Dividend Yield
—
Dilution (1yr)
+12.2%

Why Investors Own SVRA

  • ✓High-growth profile — revenue up +27.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 34% gross margin and 30% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SVRA logo

SAVARA INC

SVRA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$124M▲ +19.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$101M▲ +13.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
222.4M▲ +12.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3M▲ +$15M YoY
StockOtter · stockotter.space

About SAVARA INC

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$809.62
▲ +5.6% Upside
High Target$955.76
Low Target$740.81
Based on 17 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

SAVARA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift SVRA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

SAVARA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.